Evaxion showcases improved performance of key building block in ai-immunology™ at computational biology conference

Copenhagen, denmark, july 16, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, today showcases improved performance of its key building block, evaxmhc, within its ai-immunology™ platform, at the 32nd intelligent systems for molecular biology (ismb) conference taking place in montreal, canada, from july 12-16, 2024.
EVAX Ratings Summary
EVAX Quant Ranking